샘플 요청 목록

 카트 문의
시장보고서
상품코드
1758216

세계의 내분비 치료제 시장

Endocrinology Drugs
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 288 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 내분비 치료제 시장은 2030년까지 1,418억 달러에 도달

2024년에 945억 달러로 추정되는 세계의 내분비 치료제 시장은 분석 기간인 2024-2030년에 CAGR 7.0%로 성장하며, 2030년에는 1,418억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 당뇨병 치료제는 CAGR 7.9%를 기록하며, 분석 기간 종료시에는 692억 달러에 달할 것으로 예상됩니다. hGH 분야의 성장률은 분석 기간 중 CAGR 7.6%로 추정됩니다.

미국 시장은 257억 달러로 추정, 중국은 CAGR 11.1%로 성장 예측

미국의 내분비 치료제 시장은 2024년에 257억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 299억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 11.1%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.4%와 6.8%로 예측됩니다. 유럽에서는 독일이 CAGR 4.6%로 성장할 것으로 예측됩니다.

세계의 내분비 치료제 시장 - 주요 동향과 촉진요인 정리

내분비 질환의 치료 패러다임을 재정의하는 획기적인 치료법은?

최근 호르몬 유사체 개발, 수용체 표적치료제, 생물제제의 획기적인 발전에 힘입어 내분비 치료제에 혁신의 물결이 일고 있습니다. 과거에는 인슐린이나 레보티록신과 같은 합성 호르몬제가 주류를 이루었으나, 현재는 지속형 GLP-1 수용체 작용제, SGLT2 억제제, GLP-1과 GIP 경로를 모두 표적으로 하는 이중 작용제와 같은 차세대 약물의 도입으로 시장이 빠르게 진화하고 있습니다. 이러한 분자들은 치료 효과를 향상시킬 뿐만 아니라 심혈관 합병증, 비만 등 내분비 관련 여러 합병증에 대응하고 있습니다. 또한 내인성 호르몬 활성을 모방하여 더 높은 생체 이용률과 더 긴 반감기를 통해 투여 횟수를 최소화하고 환자의 순응도를 향상시키는 펩티드 기반 약물에 대한 연구개발 활동에도 많은 투자가 이루어지고 있습니다.

기술 혁신의 또 다른 주요 분야는 정밀 약물전달 시스템에 있습니다. 경피 패치, 피하 임플란트, 블루투스 연결 스마트 인슐린 펜은 약물 투여의 정확성과 편의성을 크게 향상시키고 있습니다. 이와 함께 바이오시밀러와 디포제제의 도입으로 말단거대증, 성장호르몬 결핍증, 쿠싱증후군과 같은 만성질환에 대한 치료가 보다 친숙하고 비용효율적으로 이루어지고 있습니다. 또한 희귀질환 치료제 지정과 FDA의 신속한 승인으로 부갑상선기능저하증, 선천성 부신과형성증과 같은 희귀질환을 대상으로 하는 새로운 내분비 치료제 시장 진입이 가속화되고 있습니다. 파이프라인은 견고하며, 새로운 저분자 및 RNA 기반 치료제로 내분비 축을 조절하는 임상시험이 증가하고 있습니다.

가장 역동적인 수요 변화를 보이는 치료 분야는?

내분비 질환은 다양하지만, 그 중에서도 당뇨병은 매출과 연구 투자 모두에서 큰 비중을 차지하며 내분비 의약품 시장을 주도하고 있으며, 2형 당뇨병 치료제는 기본적인 인슐린 대체요법부터 DPP-4 억제제, GLP-1 수용체 작용제, SGLT2 억제제 등 경구 및 주사제까지 약물로 다양화되고 있습니다. 이들은 현재 혈당 조절뿐만 아니라 심혈관 및 신장의 주요 부작용을 감소시키는 효과가 입증되어 처방되고 있습니다. 복합제 및 주 1회 투여 요법의 채택으로 환자 선호도와 복약 순응도가 향상되어 선진국과 신흥 국가 모두에서 처방량이 크게 증가하고 있습니다.

이와는 대조적으로 갑상선 질환 분야는 완만하지만 안정적인 성장세를 보이고 있으며, 그 주요 원인은 특히 요오드 결핍 지역에서 갑상선 기능 저하증의 전 세계 유병률 증가에 기인하고 있습니다. 레보티록신은 여전히 가장 표준적인 치료제로 남아 있지만, 새로운 제형, 특히 액체로 채워진 소프트젤 캡슐과 정맥 주사가 흡수 장애가 있거나 수술 전 필요한 환자들에게 선호되고 있습니다. 한편, 성장호르몬 요법은 터너 증후군, 프라더 윌리 증후군, 특발성 저신장증 등 이용 사례가 확대되고 있습니다. 바이오시밀러 의약품의 경쟁은 특히 가격 압박으로 인해 브랜드 의약품에 대한 환자 접근이 제한되는 시장에서 이 분야를 재편할 것으로 예측됩니다.

골다공증 관리 역시 데노수맙과 같은 모노클로널 항체나 아볼로파라타이드와 같은 단백 동화 약물의 도입으로 다시 주목받고 있는 분야입니다. 이러한 약제들은 폐경 후 여성과 코르티코스테로이드 유발성 골다공증 환자의 뼈 헬스케어에 혁명을 일으키고 있습니다. 마찬가지로 부신 및 뇌하수체 장애 치료제는 진단율과 호르몬 측정 기술의 향상으로 인해 3차 의료기관에서 임상적 수요가 발생하고 있습니다. 이러한 다양한 치료 분야의 역동성은 전문화 및 치료의 개별화 진전에 따른 시장 확대를 반영하고 있습니다.

지역 격차와 접근성 격차는 어떻게 시장 확대를 형성하고 있는가?

내분비 치료제 시장은 북미와 유럽이 높은 진단율, 유리한 상환 제도, 높은 환자 인지도로 인해 북미와 유럽이 가장 큰 점유율을 차지하는 등 지역 간 비대칭성이 두드러집니다. 미국은 내분비 전문 클리닉과 통합 진료 모델을 지원하는 탄탄한 인프라를 보유하고 있으며, 기술 혁신과 소비량면에서 선두를 달리고 있습니다. 다국적 제약사의 존재, 강력한 지불자-의료 프로바이더 네트워크, 약물 혁신을 촉진하는 규제 환경은 복합제 및 스마트 주사제를 포함한 새로운 치료제의 조기 도입을 가능하게 합니다. 또한 가치 기반 가격 책정 및 메디케어 확대와 같은 정책적 노력으로 내분비학 관련 처방에 대한 보험 적용이 더욱 확실해지고 있습니다.

반면, 아시아태평양과 라틴아메리카는 질병 유병률 증가와 헬스케어 정책의 발전으로 인해 고성장 지역으로 부상하고 있는 반면, 진단 부족과 제한된 내분비학 인프라가 특징입니다. 인도, 중국, 브라질과 같은 국가에서는 도시화, 라이프스타일의 변화, 고령화로 인해 당뇨병과 갑상선 질환이 급증하고 있습니다. 보편적 의료보험제도의 확대와 필수 내분비 의약품에 대한 보조금 지급을 위한 정부의 구상이 불균등하게나마 시장 진입을 촉진하고 있습니다. 바이오의약품 혁신에 주력하고 있는 것본과 한국은 현지와의 제휴 및 학술적 협력을 통해 희귀 내분비질환 치료와 정밀 내분비학의 한계를 넓혀가고 있습니다.

중동 및 아프리카는 시장 침투 측면에서 아직 시작 단계에 있는 미개발 성장 기회입니다. 이 지역에서는 다국적 기업이 교육 캠페인, 역량 개발, 단계적 가격 책정 모델 등에 투자하여 공중 보건 네트워크에 침투하기 위해 노력하고 있습니다. 그러나 공급망의 한계, 진단 능력의 편차, 내분비 전문의 밀집도 부족 등의 문제는 여전히 큰 장벽으로 남아있습니다. 전략적 파트너십, 원격의료 통합, 현지 제조를 통해 이러한 격차를 해소하는 것은 내분비 의약품의 세계 확장을 목표로 하는 기업에게 매우 중요해지고 있습니다.

내분비 치료제 시장의 성장세를 견인하는 주요 요인은 무엇인가?

내분비 치료제 시장의 성장은 혁신 파이프라인, 상업적 성공, 세계 진출 등 여러 요인에 의해 주도되고 있습니다. 특히 당뇨병, 갑상선 기능 장애, 비만, 다낭성난소증후군(PCOS)으로 대표되는 내분비 질환의 유병률이 빠르게 증가하고 있습니다. 이러한 질환은 좌식 생활방식, 식습관, 호르몬 교란 등으로 인해 모든 연령층에서 증가하고 있으며, 만성적인 치료가 필요한 환자를 광범위하게 반복적으로 양산하고 있습니다. 휴대용 진단 툴와 건강 교육 구상에 힘입어 진단 및 검진율이 높아짐에 따라 자원이 부족한 지역에서도 치료 대상 인구가 확대되고 있습니다.

또 다른 중요한 원동력은 내분비학과 디지털 건강 및 데이터 분석의 융합입니다. 스마트 주사기, 디지털 인슐린 펜, 모바일 앱과 통합된 호르몬 투여 시스템은 환자 참여, 투약 정확도, 장기적 결과를 개선하고 있습니다. 제약회사는 약리학적 이점을 넘어 부가가치 서비스를 제공하기 위해 의료 기술 및 소프트웨어 개발 회사와 협력하여 시장 차별화를 강화하고 있습니다. 동시에 전 세계에서 건강 보험 적용 범위와 정부 상환 제도의 확대로 인해 평생 내분비 치료와 관련된 경제적 장벽이 완화되고 있습니다. 이는 특히 장기적인 복약 순응도가 필요한 소아 및 노년기 내분비 질환 관리에 큰 영향을 미치고 있습니다.

공급 측면에서는 바이오시밀러, 제네릭, 국소제제의 진입으로 시장 경쟁이 치열해지면서 평균 치료비용이 낮아지고 있습니다. 특히 희귀질환을 대상으로 한 우선순위가 높은 내분비 의약품의 신속한 승인을 위한 규제 개혁은 시장 성장을 더욱 촉진하고 있습니다. 또한 내분비학에 초점을 맞춘 대형 제약회사와 바이오테크 스타트업의 R&D 투자 증가는 강력한 혁신 사이클을 촉진하고 있습니다. 호르몬 수용체 생물학, 유전체학, 분자진단학의 발전으로 인해 다음 내분비 치료제의 물결은 보다 표적화되고, 덜 침습적이며, 개별 환자 프로파일에 맞게 조정될 가능성이 높습니다. 이러한 복합적인 힘이 내분비 치료제 시장을 빠르고 지속적인 성장의 새로운 시대로 이끌고 있습니다.

부문

치료 영역(당뇨병 치료제, hGH, 갑상선 호르몬 장애, 기타 치료 영역), 유통 채널(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업의 예(주목 48사)

  • AbbVie Inc.
  • Acerus Pharmaceuticals Corp.
  • Ascendis Pharma A/S
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hanmi Pharm Co. Ltd.
  • Ipsen Pharma
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company

AI 통합

우리는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM 및 업계 고유 SLM을 조회하는 일반적인 규범을 따르는 대신에 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.07.09

Global Endocrinology Drugs Market to Reach US$141.8 Billion by 2030

The global market for Endocrinology Drugs estimated at US$94.5 Billion in the year 2024, is expected to reach US$141.8 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Diabetes Drugs, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$69.2 Billion by the end of the analysis period. Growth in the hGH segment is estimated at 7.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$25.7 Billion While China is Forecast to Grow at 11.1% CAGR

The Endocrinology Drugs market in the U.S. is estimated at US$25.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$29.9 Billion by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Endocrinology Drugs Market - Key Trends & Drivers Summarized

What Breakthroughs Are Redefining the Treatment Paradigm in Endocrine Disorders?

Recent years have seen a sweeping wave of innovation in endocrinology drugs, propelled by breakthroughs in hormone analog development, receptor-targeted therapies, and biologics. Historically dominated by synthetic hormones such as insulin and levothyroxine, the market is now rapidly evolving through the introduction of next-generation agents like long-acting GLP-1 receptor agonists, SGLT2 inhibitors, and dual agonists targeting both GLP-1 and GIP pathways. These molecules are not only enhancing therapeutic efficacy but are also addressing multiple endocrine-related comorbidities, such as cardiovascular complications and obesity. Research and development activities are also heavily invested in peptide-based drugs that mimic endogenous hormonal activities with higher bioavailability and extended half-lives, thereby minimizing dosage frequency and improving patient adherence.

Another key area of innovation lies in precision drug delivery systems. Transdermal patches, subcutaneous implants, and smart insulin pens with Bluetooth connectivity are significantly improving the accuracy and convenience of drug administration. In parallel, the introduction of biosimilars and depot formulations is making treatment for chronic conditions such as acromegaly, growth hormone deficiency, and Cushing’s syndrome more accessible and cost-efficient. Additionally, orphan drug designations and fast-track FDA approvals are accelerating market entry for novel endocrine therapies that target rare disorders like hypoparathyroidism and congenital adrenal hyperplasia. The pipeline is robust, supported by a growing number of clinical trials examining endocrine axis modulation through novel small molecules and RNA-based therapeutics, marking a sharp pivot away from traditional hormone replacement regimens.

Which Therapeutic Segments Are Witnessing the Most Dynamic Demand Shifts?

Among the diverse range of endocrine disorders, diabetes continues to dominate the endocrinology drug market, accounting for the lion’s share of both revenue and research investments. Type 2 diabetes therapies have diversified from basic insulin supplementation to include oral and injectable classes like DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors. These are now being prescribed not only for glycemic control but also for their demonstrated benefits in reducing major adverse cardiovascular and renal outcomes. The adoption of fixed-dose combinations and once-weekly dosing regimens is increasing patient preference and adherence, significantly boosting prescription volumes across both developed and emerging economies.

In contrast, the thyroid disorder segment is experiencing moderate but stable growth, largely due to the global rise in hypothyroidism prevalence, particularly in iodine-deficient regions. Levothyroxine remains the gold-standard therapy, but newer formulations-especially liquid-filled softgel capsules and IV injections-are gaining traction for patients with malabsorption issues or pre-operative needs. Meanwhile, growth hormone therapies are finding expanded use cases, including Turner syndrome, Prader-Willi syndrome, and idiopathic short stature. Biosimilar competition is expected to reshape this segment, especially in markets where pricing pressures constrain patient access to branded formulations.

Osteoporosis management is another segment experiencing renewed attention, particularly with the introduction of monoclonal antibodies such as denosumab and anabolic agents like abaloparatide. These drugs are revolutionizing bone health management for postmenopausal women and corticosteroid-induced osteoporosis cases. Similarly, adrenal and pituitary disorder therapies, though more niche in nature, are experiencing clinical demand among tertiary care centers due to improved diagnostic rates and hormonal assay techniques. Collectively, the dynamism across these diverse therapeutic segments reflects an expanding market landscape with increasing specialization and treatment personalization.

How Are Regional Disparities and Access Gaps Shaping Market Expansion?

The endocrinology drugs market displays marked regional asymmetries, with North America and Europe accounting for the largest share due to high diagnostic rates, favorable reimbursement systems, and greater patient awareness. The U.S. leads in both innovation and consumption, with a robust infrastructure supporting specialty endocrinology clinics and integrated care models. The presence of multinational pharmaceutical companies, strong payer-provider networks, and a regulatory environment that fosters drug innovation have collectively enabled earlier adoption of newer therapeutic classes, including combination drugs and smart injectables. Additionally, policy efforts like value-based pricing and Medicare expansion are ensuring better coverage for endocrinology-related prescriptions.

In contrast, Asia-Pacific and Latin America are characterized by underdiagnosis and limited endocrinology infrastructure, though they are emerging as high-growth zones due to rising disease prevalence and evolving healthcare policies. Countries like India, China, and Brazil are witnessing sharp spikes in diabetes and thyroid disorders, driven by urbanization, lifestyle shifts, and aging populations. Government efforts to expand universal health coverage and subsidize essential endocrine drugs are fueling market access, albeit unevenly. Japan and South Korea, with their strong focus on biopharmaceutical innovation, are pushing boundaries in rare endocrine disorder treatments and precision endocrinology through local partnerships and academic collaborations.

The Middle East and Africa, while still nascent in terms of market penetration, represent untapped opportunities for growth. Here, multinational companies are investing in education campaigns, capacity building, and tiered pricing models to penetrate public health networks. However, challenges such as supply chain limitations, variable diagnostic capabilities, and inadequate endocrinologist density remain formidable barriers. Addressing these disparities through strategic partnerships, telehealth integration, and local manufacturing is becoming critical for companies aiming to expand their endocrinology drug footprint globally.

What Key Forces Are Powering the Growth Trajectory of the Endocrinology Drugs Market?

The growth in the endocrinology drugs market is driven by several factors that collectively shape its innovation pipeline, commercial success, and global reach. Chief among these is the rapidly increasing prevalence of endocrine disorders, led by diabetes, thyroid dysfunction, obesity, and polycystic ovary syndrome (PCOS). These conditions are rising across all age groups due to sedentary lifestyles, poor dietary habits, and hormonal disruptions, thereby creating a broad and recurring patient base requiring chronic treatment. The growing diagnosis and screening rates, aided by portable diagnostic tools and health education initiatives, are expanding the treated population even in resource-constrained regions.

Another key driver is the convergence of endocrinology with digital health and data analytics. Smart injectables, digital insulin pens, and hormone delivery systems integrated with mobile apps are improving patient engagement, dosage accuracy, and long-term outcomes. Pharmaceutical companies are collaborating with medtech and software developers to offer value-added services that go beyond pharmacological benefits, thereby enhancing market differentiation. Simultaneously, the global expansion of health insurance coverage and government reimbursement schemes is reducing the financial barriers associated with lifelong endocrine therapies. This is particularly impactful in the management of pediatric and geriatric endocrine disorders, which require long-term medication adherence.

From a supply-side perspective, the entry of biosimilars, generics, and local formulations is intensifying market competition and bringing down the average cost of treatment. Regulatory reforms that fast-track the approval of high-priority endocrine drugs, especially those targeting orphan conditions, are further catalyzing market growth. Additionally, rising investment in endocrinology-focused R&D by both large pharmaceutical firms and biotech startups is fueling a robust innovation cycle. With advancements in hormone receptor biology, genomics, and molecular diagnostics, the next wave of endocrine drugs is likely to be more targeted, less invasive, and tailored to individual patient profiles. These combined forces are propelling the endocrinology drugs market into a new era of rapid and sustainable growth.

SCOPE OF STUDY:

The report analyzes the Endocrinology Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Area (Diabetes Drugs, hGH, Thyroid Hormone Disorders, Other Therapy Areas); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AbbVie Inc.
  • Acerus Pharmaceuticals Corp.
  • Ascendis Pharma A/S
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • Eli Lilly and Company
  • Endo International plc
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hanmi Pharm Co. Ltd.
  • Ipsen Pharma
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Endocrinology Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Diabetes and Thyroid Disorders Drives Demand for Endocrinology Therapies
    • Expansion of Personalized Hormonal Treatment Plans Strengthens Business Case for Targeted Endocrine Drugs
    • Advancements in GLP-1 Receptor Agonists and SGLT2 Inhibitors Spur Innovation in Diabetes Drug Portfolios
    • Increased Use of Biosimilars in Hormone Replacement Therapy Expands Patient Access in Cost-Conscious Markets
    • Integration of Digital Health Platforms for Disease Monitoring Enhances Adherence to Endocrinology Medications
    • Development of Dual and Triple-Action Injectable Therapies Propels Growth in Metabolic Disease Management
    • Regulatory Approvals for Once-Weekly and Extended-Release Formulations Drive Patient-Centric Product Development
    • Growing Awareness of Pediatric Endocrine Disorders Expands Market for Specialized Drug Formulations
    • Emergence of AI-Based Diagnostic Tools Throws Spotlight on Early Detection and Hormone-Based Intervention
    • Rising Demand for Fertility Hormones and Gonadotropins Accelerates Growth in Reproductive Endocrinology Segment
    • Government-Led Public Health Campaigns Boost Awareness and Diagnosis of Endocrine Disorders
    • Clinical Research Advancements in Rare Endocrine Diseases Generate Pipeline Activity in Orphan Drug Development
    • Shift Toward Preventive Treatment of Pre-Diabetes and Subclinical Thyroid Conditions Drives Market Expansion
    • Adoption of Companion Diagnostics Strengthens Drug Efficacy in Personalized Endocrinology Treatment Plans
    • Growth in Elderly Population and Age-Related Hormonal Deficiencies Fuels Long-Term Drug Adherence
    • Increased Focus on Safety and Tolerability of Long-Term Endocrine Therapies Encourages Drug Reformulations
    • Strategic Collaborations Between Pharma and Endocrine Clinics Support Clinical Trial Recruitment and Real-World Evidence
    • Emerging Biotech Firms Driving Disruption in Novel Hormonal and Metabolic Pathway Therapeutics
    • Stringent Regulatory Review Processes for Endocrine Drug Approvals Challenge Time-to-Market for New Molecules
    • Expansion of Telemedicine and Remote Prescription Models Facilitates Greater Access to Endocrinology Medications
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Endocrinology Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Endocrinology Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Endocrinology Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Endocrinology Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Diabetes Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Diabetes Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Diabetes Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for hGH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for hGH by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for hGH by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Thyroid Hormone Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Thyroid Hormone Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Thyroid Hormone Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapy Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Therapy Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Therapy Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • JAPAN
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • CHINA
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • EUROPE
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Endocrinology Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Endocrinology Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Endocrinology Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • FRANCE
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • GERMANY
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Endocrinology Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Endocrinology Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Endocrinology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • INDIA
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Endocrinology Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Endocrinology Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Endocrinology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Endocrinology Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Endocrinology Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Endocrinology Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030
  • AFRICA
    • Endocrinology Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Endocrinology Drugs by Therapy Area - Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Endocrinology Drugs by Therapy Area - Percentage Breakdown of Value Sales for Diabetes Drugs, hGH, Thyroid Hormone Disorders and Other Therapy Areas for the Years 2014, 2025 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Endocrinology Drugs by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Endocrinology Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제